You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Systemic Therapy for Small-Cell Lung Cancer: ASCO-Ontario Health (Cancer Care Ontario) Guideline

Version: 3 ID: 7-A-2022-1-17v3 Oct 2023
Type of Content: Guidelines & Advice, Clinical
Document Status: Current
Humera Khurshid, Nofisat Ismaila, Jessica Bian, Raetasha Dabney, Millie Das, Peter Ellis, Jill Feldman, Christine Hann, Swati Kulkarni, Janessa Laskin, Rami Manochakian, Deebya Raj Mishra, Isabel Preeshagul, Pavan Reddy, Ashish Saxena, Frank Weinberg, Gregory P. Kalemkerian


This clinical practice guideline was produced jointly by the American Society of Clinical Oncology (ASCO) and Ontario Health (Cancer Care Ontario) (OH CCO). The aim is to provide evidence-based recommendations to practicing clinicians on the management of patients with small-cell lung cancer. The joint guideline is published in the Journal of Clinical Oncology (JCO) and can be accessed directly from the link "Full Report" below.

Patient Population

Patients with small-cell lung cancer.

Intended Guideline Users

Medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, pathologists, radiologists, primary care physicians, nurse practitioners, physician assistants, pharmacists, nurses, and other providers.

Research Question

What is the optimal systemic therapy for patients with small-cell lung cancer (SCLC)?

pdf download Full Report (PDF) (965.23 KB)